NewCardio is cardiac diagnostic technology provider, announced that on January 12, 2010, it received notice of allowance for U.S. patent 7,647,093, titled “Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing,” from the U.S. Patent and Trademark Office. This represents the core patent for CardioBip(TM) and, in conjunction with the two encouraging validation studies announced on January 5, 2010, validates the CardioBip technology, positioning NewCardio as an emerging leader in remote cardiac monitoring.
The CardioBip is a unique, hand-held device that provides a solution for ECG telemonitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device’s electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.
Branislav Vajdic, Ph.D., chief executive officer of NewCardio, Inc., commented, “This patent strengthens our intellectual property protection creating a significant barrier to entry for a competing device. We believe the CardioBip technology fills an important technological and diagnostic void, enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity. At present there is no convenient and reliable method for remote monitoring and detection of either ischemic events or derangements of atrial electrical activity, but this patent and the two recently completed validation studies indicate that the CardioBip may potentially fill this need. This patent protects the core technology underlying the CardioBip. The patent comes immediately following the encouraging results from two validation studies, which confirmed CardioBip’s ability to record, reconstruct and transmit an accurate, high-resolution 12-lead ECG. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences. We are gratified by the U.S. Patent and Trademark Office’s grant of patent rights and pleased that they approved all 33 claims.”
Dorin Panescu, Ph.D., NewCardio’s Vice President and Chief Technology Officer: “These encouraging study results confirm the CardioBip’s ability to record, reconstruct and transmit an accurate, high-resolution 12-lead ECG, thereby enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity. The Heart Rhythm Society (HRS) Expert Consensus recommends ongoing monitoring for up to two years following catheter or surgical atrial fibrillation (AF) ablation procedures, and our results suggest that the CardioBip may prove particularly useful in detecting AF recurrence after such procedures.”
NewCardio (NWCI) shares rose 98 % to $ 1.88 per week.
NewCardio is a Silicon Valley based company with the mission of fully developing and commercializing a three dimensional (3D) approach to electrocardiography.
The company is developing and validating a novel, patent pending electrocardiography (ECG) platform technology to dramatically improve the diagnostic accuracy and value of the standard 12 lead ECG for common acute and chronic heart disease and for evaluating cardiac safety of new drugs. NewCardio platform technology relies on the standard 12-lead ECG signal as the input, and thus requires no change in how the 12-lead ECG is obtained.
NewCardio’s cardiac diagnostic products and services are used to determine the cardiac toxicity of new drugs in development, and to evaluate cardiac status during acute and chronic patient management both in and out of the clinical environment. NewCardio’s 3-dimensional ECG approach allows faster, more accurate and less expensive assessment of cardiac status, and diagnosis of previously difficult or undiagnosable conditions, without much more expensive and not as widely available techniques.
NewCardio’s services for clinical drug trials will help ECG core labs and pharmaceutical and biotech companies to rapidly detect cardiac toxicity, when present, for drugs involved in clinical development. In healthcare, the Company’s diagnostic tools will substantially improve the accuracy and timeliness of the diagnosis and response to patients arriving at the emergency department with suspected myocardial infarction (MI). NewCardio’s hand-held products could change the way patients with chronic heart conditions will monitor their disease outside the clinical setting.